Skip to main content
. 2018 Mar 21;8:4935. doi: 10.1038/s41598-018-23003-3

Figure 5.

Figure 5

Dex treatment protected synaptic degeneration in the cortex after moderate TBI. Analysis of intensity of synaptophysin staining of the selected tissue area was performed at 10× magnification first, and then 3 regions in the cortex of each group were chosen for accurate recognition at 60× magnification according to the distance from the lesion cortex. (A) Synaptophysin staining in the sham group at 10× magnification. (B–D) Synaptophysin staining in the sham group at 60× magnification. (E) Synaptophysin staining in the traumatic brain injury (TBI) group at 10× magnification. (F) Synaptophysin staining in the TBI group 200 µm from the lesion cortex. (G) Synaptophysin staining in the TBI group 400 µm from the lesion cortex. (H) Synaptophysin staining in the TBI group 800 µm from the lesion cortex. (I) Synaptophysin staining in the 100 µg/kg dexmedetomidine (Dex) treatment group at 10× magnification. (J) Synaptophysin staining in the 100 µg/kg Dex treatment group 200 µm from the lesion cortex. (K) Synaptophysin staining in the 100 µg/kg Dex treatment group 400 µm from the lesion cortex. (L) Synaptophysin staining in the 100 µg/kg Dex treatment group 800 µm from the lesion cortex.